Peptide CJC-1295 (DAC-GRF) is a synthetic and modified analogue of endogenous peptide hormone called Growth hormone-releasing hormone (GHRH, somatocrinin), its chain consists of 30 amino acid. CJC-1295 significantly increases plasma growth hormone and IGF-1 (insulin-like growth factor 1) levels in the body, and it is one of the most effective peptide for growth hormone optimization. CJC-1295 stimulates GH production and release by binding to the GHRH receptor (GHRHR) on cells in the anterior pituitary, and can be very good combined (stacked) with other GHR peptides (GHRP-6, Ipamorelin and similar) for synergistic effect.
CJC-1295 chemical structure
A chemical structure of a CJC-1295 molecule includes the arrangement of atoms and the chemical bonds that hold the atoms together. The CJC 1295 molecule contains a total of 492 bond(s) There are 240 non-H bond(s), 55 multiple bond(s), 118 rotatable bond(s), 37 double bond(s), 18 aromatic bond(s), 3 six-membered ring(s), 2 carboxylic acid(s) (aliphatic), 4 primary amide(s) (aliphatic), 28 secondary amide(s) (aliphatic), 3 guanidine derivative(s), 6 primary amine(s) (aliphatic), 3 secondary amine(s) (aliphatic), 6 hydroxyl group(s), 2 aromatic hydroxyl(s), 3 primary alcohol(s) and 1 secondary alcohol(s).
Growth hormone–releasing hormone (Somatocrinin)
Growth hormone–releasing hormone (GHRH; somatocrinin) is a 44-amino acid endogenous peptide hormone, released from neurosecretory nerve terminals of these arcuate neurons in a pulsatile manner (what also leads to the pulsatile release of growth hormone and also affects slow-wave sleep directly). GHRH is carried by the hypothalamo-hypophyseal portal system to the anterior pituitary gland, where it stimulates growth hormone (GH) secretion by binding the growth hormone-releasing hormone receptor (GHRHR).
Growth hormone-releasing hormone receptor (GHRHR)
The GHRHR is a member of the secretin family of G protein-coupled receptors, and is located on chromosome 7. This protein is transmembranous with seven folds, and its molecular weight is approximately 44 kD. GHRH binding to GHRHR results in increased GH production mainly by the cAMP-dependent pathway, but also by the phospholipase C pathway (IP3/DAG pathway), and other minor pathways.
Growth-hormone-inhibiting hormone (Somatostatin)
Above mentioned actions of GHRH are opposed by somatostatin (growth-hormone-inhibiting hormone), that is released from neurosecretory nerve terminals of periventricular somatostatin neurons, and is carried by the hypothalamo-hypophysial portal circulation to the anterior pituitary where it inhibits GH secretion. Somatostatin and GHRH are secreted in alternation, giving rise to the markedly pulsatile secretion of growth hormone.
Clinical trials and CJC-1295 results
CJC-1295 was under investigation for the treatment of lipodystrophy and growth hormone deficiency. With a single injection, in human subjects, CJC-1295 increases plasma GH levels by 2-10 fold for 6 days or longer and plasma insulin-like growth factor 1 levels by 1.5-3 fold for 9 to 11 days. CJC-1295 has an estimated half-life of about 6 to 8 days in humans (that is significantly prolonged by bioconjugation), and with multiple doses of CJC-1295, IGF-1 levels were found to remain elevated in humans for up to 28 days.
Scientifically investigated possible benefits of CJC-1295
- CJC-1295 increases the secretion of growth hormone
- CJC-1295 improves overall regeneration and cellular repair
- CJC-1295 boosts protein synthesis and promotes lean muscle mass growth
- CJC-1295 helps to increase bone density
- CJC-1295 helps to burn excess body fat
- CJC-1295 provides anti-aging effects and rejuvenation
- CJC-1295 supports feeling of energy, vitality and freshness
- CJC-1295 helps to improve skin health
- CJC-1295 strengthens the immune system
- CJC-1295 supports cognitive functions
CJC-1295 possible side-effects
- CJC-1295 may provide tingling or numbing sensation in feet and hands
- CJC-1295 may cause euphoria between 30 – 120 minutes after the injection
- CJC-1295 may cause aches in joints
- CJC-1295 may cause low blood sugar
- Mild irritation on the injection site of CJC-1295
- CJC-1295 may cause excessive water retention
- CJC-1295 may decrease insulin sensitivity
In the scientific study and clinical trial performed, subcutaneous administration of CJC-1295 to healthy adults (ages 21–61 years) was safe and relatively well tolerated, even at higher doses of 30 to 60 mcg / kg: After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2 to 10 fold for 6 days or more, and in mean plasma IGF-1 concentrations by 1.5 to 3 fold for 9–11 days. The estimated half-life of CJC-1295 was 5.8–8.1 days. After multiple CJC-1295 doses, mean IGF-1 levels remained above baseline for up to 28 days. At this study, no serious adverse reactions were reported. However (in accordance with our opinion), as optimal dosing would rather be considered no more than 300-500 mcg of CJC-1295 in single injection or weekly total.